Navigation Links
New technology improves heart rhythm treatment
Date:7/18/2012

Researchers from UC San Diego, the University of California Los Angeles and Indiana University report having found, for the first time, that atrial fibrillation or irregular heart rhythms is caused by small electrical sources within the heart, in the form of electrical spinning tops ("rotors") or focal beats. Importantly, they found a way of detecting these key sources, then precisely targeting them for therapy that can shut them down in minutes with long lasting results.

The team, which included cardiologists, physicists and bioengineers, report the findings in the July issue of the Journal of the American College of Cardiology as the CONFIRM trial (Conventional Ablation for Atrial Fibrillation
With or Without Focal Impulse and Rotor Modulation).

Currently, many patients treated for atrial fibrillation with standard therapies will experience a recurrence due to the difficulty of finding the source of the arrhythmia. The new findings will help cardiologists better target and treat arrhythmias.

The CONFIRM study examined 107 patients with atrial fibrillation referred for a non-surgical catheter ablation procedure. During this procedure, doctors thread a wire with a metal-tipped catheter inside the body, from a vein in the groin, to apply heat to the area of the heart that is producing the arrhythmia to stop it.

In one group of patients, the team used the new technique to help perform precise burns, called Focal Impulse and Rotor Modulation (FIRM) that were aimed directly at the fundamental source of the arrhythmia tiny electrical disturbances in the heart called rotors or focal sources that look like mini tornadoes or spinning tops.

Remarkably, this new procedure shut down atrial fibrillation or very significantly slowed it in 86 percent of patients in an average of only 2.5 minutes.

In comparison, conventional catheter procedures were performed in a second group of patients. Since this approach is less targeted, it involved hours of treatment over larger regions in the heart and often did not shut down the atrial fibrillation.

To track outcomes, patients received an implanted ECG monitor that very accurately assessed their heart rhythms over time. Researchers found that after two years, the FIRM-guided group had an 82.4 percent freedom from atrial fibrillation episodes, compared to only 44.9 percent freedom in the group that received standard therapy.

The new targeted method demonstrated an 86 percent improvement over the conventional method in the study.

"We are very excited by this trial, which for the first time shows that atrial fibrillation is maintained by small electrical hotspots, where brief FIRM guided ablation can shut down the arrhythmia and bring the heart back to a normal rhythm after only minutes of ablation," said lead author Sanjiv Narayan, MD, PhD, professor of medicine at UC San Diego Sulpizio Cardiovascular Center, director of Electrophysiology at the San Diego Veterans Affairs Medical Center and visiting professor at the UCLA Cardiac Arrhythmia Center.

"The results of this trial, with an 80 percent ablation success rate after a single procedure, are very gratifying. This is the dawn of a new phase of managing this common arrhythmia that is mechanism-based," said Kalyanam Shivkumar, MD, PhD, director of the UCLA Cardiac Arrhythmia Center, and professor of medicine and radiological sciences at UCLA.


'/>"/>

Contact: Kim Edwards
kedwards@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert  

Related medicine news :

1. Researchers to use novel metabolomics technology for COPD
2. University of Minnesota licenses Clinical Decision Support technology
3. Newer technology to control blood sugar works better than conventional methods
4. 3M™ Gripping Material Technology – Giving Golfers a Competitive Edge
5. IVR Technology Group Named Platimum VAR by TSYS
6. FDA Approves SonixGPS Needle Guidance Technology for Vascular Access Procedures
7. Miami Children’s Hospital Performs First Nerve Repair Surgery Using Avance® Nerve Graft Technology
8. Swanson Health Products Introduces a New Alkalizing Drink Mix, Swanson® pH Balance Alka-Tone with Alka-Plex™ Technology
9. The Casey Group's Sales Navigator Wins 2012 Best Mobility App in the New Jersey Technology Council's Mobile Application Competition
10. Simulation technology allows users to safely practice phacoemulsification cataract surgery
11. Power generation technology based on piezoelectric nanocomposite materials developed by KAIST
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New technology improves heart rhythm treatment
(Date:12/2/2016)... ... December 02, 2016 , ... Yisrayl Hawkins, at The House of Yahweh ... generation fits into Bible Prophecy. Yisrayl says this generation, known as the Last Generation, ... showing how the details line up exactly with Bible Prophecy – a protected way ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health ... has raised $6.0 million in an initial round of funding. The round was ... and their caregivers can receive far better care through the application of the ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today CloudMine, a secure, ... was named the best Sales Team of 2016 as part of the 2016 ... by the Software & Information Industry Association (SIIA), the principal trade association for ...
(Date:12/2/2016)... FL (PRWEB) , ... December 02, 2016 , ... ‘Tis ... are winners of $1,000 each from the National Family Partnership and the Drug Enforcement ... families who decorated their homes and the 10 winning schools who decorated their campuses ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... they now offer a comprehensive in-house dental plan for all patients. Understanding that ... a plan that gives patients a number of perks, including discounts on many ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2016 Orthopedic Implants (Including Spinal Implants, ... to Gain a Significant Market Share Owing to a Large ... ... According to a new report by Persistence ... Packaging: Clamshell Product Type Segment Projected to Witness a Significantly ...
(Date:12/2/2016)... MONMOUTH JUNCTION, N.J. , Dec. 2, 2016 /PRNewswire/ ... critical care immunotherapy leader commercializing its European Union approved ... in critically-ill and cardiac surgery patients worldwide, announced that ... present at the 9th Annual LD Micro Main ... 8 th , 2016 at the Luxe Sunset Boulevard ...
(Date:12/2/2016)... NEW YORK , December 2, 2016 ... at 5,251.11, down 1.36%; the Dow Jones Industrial Average edged ... closed at 2,191.08, down 0.35%. Losses were broad based as ... Today, Stock-Callers.com has initiated research reports on the following Services ... N.V. (NASDAQ: QGEN ), INC Research Holdings Inc. ...
Breaking Medicine Technology: